The company is an international contract research organization (CRO). The company’s primary services include consultation for technology transfer and drug development and manufacturing.

Key Aspects

Operating in growth mode; revenues and adjusted EBITDA grew at a compound annual growth rate (CAGR) of 107.1% and 77.9% from FY 2018 to 2021, respectively
Adjusted EBITDA margins have averaged 18.3% from FY 2018 to 2021
Extensive expert resources combining unique processes and full technology integration
Client base located worldwide
Large database of proprietary drug development and manufacturing resources
In operation for over 15 years

Opportunities

Capitalize on the highly scalable and profitable resources and methodology that the company currently has in place
Expand customer base to include a greater amount of pharmaceutical companies
Capitalize on an existing revenue model to drive growth in a rapidly growing industry

Headquartered

British Columbia

Potential Markets

The company currently serves small and medium-sized pharmaceutical companies located around the world.

Real Estate

The company operates from a 3,000 sq. ft. facility leased from an unrelated third party. There is room to grow in the current location.

Shareholder Objectives

The company is owned by a single shareholder. He believes the company is in a position to expand and take advantage of growth opportunities in the industry. The shareholder is seeking to pursue different activities; however, he is willing to stay with the company under new ownership for a transition period.

Benchmark International

Benchmarks Exclusive Opportunities

International Pharmaceutical Contract Research Organization – BN000033899

International Pharmaceutical Contract Research Organization – BN000033899

Login